Tag: Prescription Drugs

Enrollment stopped for futility based on no difference in pulmonary function on day 5 compared with placebo

No significant difference seen in mean visual acuity letter score over 24 weeks for patients with proliferative diabetic retinopathy

Current approval of the once-daily tablet indicated for patients who have undergone complete tumor removal

Increased risk for breast cancer observed, which was seen for up to two years after discontinuation of oral contraceptives

Mean number of migraine days per month lower in those receiving rimegepant versus placebo

Cocktail of two antibodies against SARS-CoV-2 spike protein reduces viral load, with greater effect in antibody-negative patients

Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i

But death from any cause by day 28 in those hospitalized with COVID-19 pneumonia did not differ for tocilizumab versus placebo

Mixed results seen for effect of siponimod on cognitive processing speed in patients with secondary progressive multiple sclerosis

After CDC guideline publication, there was a 14 percent decrease in oxycodone prescriptions, but not for other Schedule II opioids